Almirall S.A. stock (ES0157097017): Reiterates 2026 earnings guidance

Almirall S.A. confirmed its full-year 2026 earnings outlook on May 11, amid updates to its scrip dividend pricing. The Spanish pharma firm focuses on dermatology and cannabinoid therapies.

Almirall S.A. reiterated its earnings guidance for the full year 2026 on May 11, 2026, signaling confidence in its strategic trajectory, according to MarketScreener as of May 11, 2026. The company also amended the weighted average share price for its scrip dividend on May 12, reflecting ongoing shareholder return efforts. These developments come as Almirall advances its pipeline in immunology and dermatology, areas with strong US market relevance.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Almirall, S.A.
• Sector/industry: Pharmaceuticals
• Headquarters/country: Spain
• Core markets: Europe, US
• Key revenue drivers: Dermatology, respiratory drugs
• Home exchange/listing venue: Madrid (ALM)
• Trading currency: EUR

Almirall S.A.: core business model

Almirall S.A. develops and commercializes pharmaceutical products primarily in dermatology, cannabinoid science, and immunology. The company, headquartered in Barcelona, Spain, markets branded drugs like Skilarence for psoriasis and Efficera for actinic keratosis. Its business model emphasizes innovation in underserved therapeutic areas, with a focus on specialty care rather than mass-market generics. Almirall generates revenue through direct sales in Europe and partnerships for global reach, including the US where dermatology demand drives growth.

This model supports stable cash flows from established products while investing in R&D for next-generation therapies. For US investors, Almirall's exposure to the $15 billion US dermatology market, per IQVIA data published in 2025, offers a play on rising skin disorder prevalence amid aging populations.

Main revenue and product drivers for Almirall S.A.

Key products include Sebiprox for seborrheic dermatitis and a growing cannabinoid portfolio targeting chronic pain and inflammation. In Q1 2026 results published April 2026, dermatology sales rose 8% year-over-year, comprising over 60% of revenue, according to the company's IR site Almirall IR as of May 2026. Respiratory drugs like aclidinium bromide add diversification.

Pipeline catalysts include phase III trials for oral psoriasis treatments, with data expected in late 2026. These drivers position Almirall to capture share in high-margin specialty pharma, relevant for US portfolios seeking European biotech with transatlantic potential.

Industry trends and competitive position

The dermatology sector grows at 7% CAGR through 2030, fueled by biologics and topicals, per EvaluatePharma forecasts from 2025. Almirall competes with giants like AbbVie and Leo Pharma but differentiates via niche cannabinoid therapies. Its 2026 guidance reaffirmation underscores resilience amid patent cliffs faced by peers.

Why Almirall S.A. matters for US investors

Listed on Madrid's BME, Almirall trades as ADRs in the US, providing easy access via OTC markets. With 20% of sales from North America as of 2025 annual report, it ties into US healthcare spending trends. The recent guidance hold offers visibility into earnings stability for dividend-focused portfolios.

Conclusion

Almirall S.A.'s recent guidance reiteration and scrip dividend adjustment highlight operational steadiness in a competitive pharma landscape. With a solid dermatology franchise and US market exposure, the company navigates growth opportunities while managing R&D costs. Investors track pipeline milestones and sector dynamics for ongoing developments.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.